Skip to main content
S&P 5007,376.86+0.31%DOW51,285.73-0.46%NASDAQ24,579.42+1.09%BTC$75,946.00-0.25%ETH$2,243.57+0.21%GOLD$4,079.50-0.83%OIL$90.34-0.20%
Smart Investors Daily
SID Premium
PM

NASDAQ · PMN

ProMIS Neurosciences, Inc.

Healthcare · Biotechnology

$4.16

Up+$0.51 (+13.97%)

Updated Nov 8, 2026, 8:22 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.34M
P/E ratio
-0.41
Dividend yield
0.00%
52-week range
$2.78 – $27.40
Volume
375.16K
Avg. volume
31.52K

Price performance · PMN

PMN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 6, 2026

PMN closed at $4.16 after 20 trading sessions, down 55.98% for the selected period.

Last close
$4.16
Period change
-55.98%
Period low
$3.00
Period high
$11.08
Daily close
View OHLC price history
PMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 6, 2026$3.76$4.33$3.70$4.16375.16K
Nov 5, 2026$3.55$3.76$3.40$3.65272.1K
Nov 4, 2026$3.41$3.54$3.02$3.52517.02K
Nov 3, 2026$3.29$3.62$3.28$3.41995.25K
Nov 2, 2026$3.59$4.50$2.7801$3.003.54M
Oct 30, 2026$8.41$8.5299$3.21$3.311.64M
Oct 29, 2026$10.87$11.38$10.35$11.08132.85K
Oct 28, 2026$9.58$11.76$9.58$11.0750.65K
Oct 27, 2026$8.36$10.28$8.36$9.6853.06K
Oct 26, 2026$8.46$8.87$7.7426$8.0622K
Oct 23, 2026$8.65$8.80$8.24$8.3410.44K
Oct 22, 2026$9.06$9.31$8.88$8.986.44K
Oct 21, 2026$8.40$9.13$8.18$9.137.49K
Oct 20, 2026$8.34$8.65$8.06$8.0930.25K
Oct 19, 2026$8.36$8.385$8.06$8.2311.34K
Oct 16, 2026$8.89$9.64$7.935$8.1520.42K
Oct 15, 2026$8.29$8.87$8.00$8.7033.54K
Oct 14, 2026$8.41$8.81$8.16$8.28523.38K
Oct 13, 2026$9.38$9.47$8.51$8.6627.13K
Oct 12, 2026$9.61$9.78$9.20$9.4523.73K

Latest PMN news

The latest Smart Investors Daily articles mentioning PMN.

Stock researchCompany · Overview

PMN research

Overview

Company profile and research snapshot.

Company profile

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
PMN recent ratings
DateFirmRatingTarget
Nov 2, 2026Roth CapitalBuy—
Aug 14, 2026GuggenheimBuy—
Jul 29, 2026GuggenheimBuy—
Jul 28, 2026Chardan CapitalBuy—
Jul 27, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

ProMIS Neurosciences to Participate in Upcoming Conferences in November

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company’s leadership team will be available for one-on-o

Yahoo · Nov 3, 2026

ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026

Company to host investor conference call and webcast at 4:30 p.m. ET.Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the third quarter ended September 30, 2026, and provide corporate updates on November 12, 2026. The company will host a confer

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By